TWI846229B - 布魯頓氏酪胺酸激酶之抑制劑 - Google Patents

布魯頓氏酪胺酸激酶之抑制劑 Download PDF

Info

Publication number
TWI846229B
TWI846229B TW111149550A TW111149550A TWI846229B TW I846229 B TWI846229 B TW I846229B TW 111149550 A TW111149550 A TW 111149550A TW 111149550 A TW111149550 A TW 111149550A TW I846229 B TWI846229 B TW I846229B
Authority
TW
Taiwan
Prior art keywords
tert
tetrahydro
benzo
butyl
pyrazol
Prior art date
Application number
TW111149550A
Other languages
English (en)
Chinese (zh)
Other versions
TW202315870A (zh
Inventor
布萊恩 T 哈柏金
馬斌
羅賓 普林斯
以撒 馬克思
喬瑟夫 P 萊多斯
鳳妹 鄭
馬修 彼得森
丹尼爾 B 佩西恩斯
Original Assignee
美商百健Ma公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百健Ma公司 filed Critical 美商百健Ma公司
Publication of TW202315870A publication Critical patent/TW202315870A/zh
Application granted granted Critical
Publication of TWI846229B publication Critical patent/TWI846229B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW111149550A 2017-04-14 2018-04-13 布魯頓氏酪胺酸激酶之抑制劑 TWI846229B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485745P 2017-04-14 2017-04-14
US62/485,745 2017-04-14

Publications (2)

Publication Number Publication Date
TW202315870A TW202315870A (zh) 2023-04-16
TWI846229B true TWI846229B (zh) 2024-06-21

Family

ID=62092333

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111149550A TWI846229B (zh) 2017-04-14 2018-04-13 布魯頓氏酪胺酸激酶之抑制劑
TW107112785A TWI790227B (zh) 2017-04-14 2018-04-13 布魯頓氏酪胺酸激酶之抑制劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107112785A TWI790227B (zh) 2017-04-14 2018-04-13 布魯頓氏酪胺酸激酶之抑制劑

Country Status (36)

Country Link
US (5) US10227341B2 (cg-RX-API-DMAC7.html)
EP (2) EP4249071A3 (cg-RX-API-DMAC7.html)
JP (3) JP7145874B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250140646A (cg-RX-API-DMAC7.html)
CN (2) CN117567453A (cg-RX-API-DMAC7.html)
AR (2) AR111594A1 (cg-RX-API-DMAC7.html)
AU (3) AU2018253209B2 (cg-RX-API-DMAC7.html)
CA (1) CA3058774A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002900A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019012571A2 (cg-RX-API-DMAC7.html)
CR (2) CR20190517A (cg-RX-API-DMAC7.html)
DK (1) DK3609886T3 (cg-RX-API-DMAC7.html)
EA (1) EA201992354A1 (cg-RX-API-DMAC7.html)
ES (1) ES2975769T3 (cg-RX-API-DMAC7.html)
FI (1) FI3609886T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240361T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066253T2 (cg-RX-API-DMAC7.html)
IL (3) IL269933B (cg-RX-API-DMAC7.html)
JO (1) JOP20190233B1 (cg-RX-API-DMAC7.html)
LT (1) LT3609886T (cg-RX-API-DMAC7.html)
MA (1) MA50013B1 (cg-RX-API-DMAC7.html)
MD (1) MD3609886T2 (cg-RX-API-DMAC7.html)
MX (1) MX2023000812A (cg-RX-API-DMAC7.html)
PE (2) PE20240930A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502334A1 (cg-RX-API-DMAC7.html)
PL (1) PL3609886T3 (cg-RX-API-DMAC7.html)
PT (1) PT3609886T (cg-RX-API-DMAC7.html)
RS (1) RS65386B1 (cg-RX-API-DMAC7.html)
SA (1) SA519410292B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201909224QA (cg-RX-API-DMAC7.html)
SI (1) SI3609886T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400166T1 (cg-RX-API-DMAC7.html)
TW (2) TWI846229B (cg-RX-API-DMAC7.html)
UA (1) UA127347C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018191577A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306172B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
RS65386B1 (sr) 2017-04-14 2024-04-30 Biogen Ma Inc Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze
US11820760B2 (en) 2018-10-15 2023-11-21 Biogen Ma Inc. Crystalline polymorphs of Bruton's tyrosine kinase inhibitors
JP7747523B2 (ja) * 2019-05-15 2025-10-01 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
US20240216330A1 (en) * 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023086521A1 (en) 2021-11-10 2023-05-19 Biogen Ma Inc. Btk inhibitors
CA3240051A1 (en) 2021-12-30 2023-07-06 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029046A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
WO2014125444A1 (en) * 2013-02-15 2014-08-21 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
WO2015089337A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
ES2406129T3 (es) 2007-10-05 2013-06-05 Verastem, Inc. Derivados de purina sustituidos con pirimidina
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
US20140357636A1 (en) 2013-02-21 2014-12-04 Wayne Rothbaum Treatment of Skeletal-Related Disorders
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
CN107001362A (zh) 2014-10-06 2017-08-01 默克专利有限公司 用作btk抑制剂的杂芳基化合物及其用途
RS65386B1 (sr) 2017-04-14 2024-04-30 Biogen Ma Inc Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029046A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
WO2014125444A1 (en) * 2013-02-15 2014-08-21 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
WO2015089337A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Also Published As

Publication number Publication date
IL316713A (en) 2024-12-01
PE20240930A1 (es) 2024-04-30
EA201992354A1 (ru) 2020-03-10
CA3058774A1 (en) 2018-10-18
JP2022180498A (ja) 2022-12-06
CL2019002900A1 (es) 2020-01-24
US20180362522A1 (en) 2018-12-20
EP3609886B1 (en) 2024-02-07
US20210340135A1 (en) 2021-11-04
TW201841909A (zh) 2018-12-01
JOP20190233A1 (ar) 2019-10-02
JP2025020247A (ja) 2025-02-12
US11427577B2 (en) 2022-08-30
PT3609886T (pt) 2024-04-11
MD3609886T2 (ro) 2024-07-31
ZA202306172B (en) 2024-11-27
US10227341B2 (en) 2019-03-12
HUE066253T2 (hu) 2024-07-28
UA127347C2 (uk) 2023-07-26
CN117567453A (zh) 2024-02-20
CN110621670A (zh) 2019-12-27
PL3609886T3 (pl) 2024-05-13
KR20250140646A (ko) 2025-09-25
AR111594A1 (es) 2019-07-31
BR112019021399A2 (pt) 2020-04-28
JP2020516659A (ja) 2020-06-11
MX2023000812A (es) 2023-02-27
IL294175B2 (en) 2025-04-01
KR102862996B1 (ko) 2025-09-22
KR102607900B1 (ko) 2023-11-29
DK3609886T3 (da) 2024-03-18
SMT202400166T1 (it) 2024-07-09
AU2018253209B2 (en) 2022-06-02
KR20190139926A (ko) 2019-12-18
JP7778206B2 (ja) 2025-12-01
TW202315870A (zh) 2023-04-16
PH12019502334A1 (en) 2020-09-21
PE20200740A1 (es) 2020-07-24
AU2018253209A1 (en) 2019-10-31
TWI790227B (zh) 2023-01-21
IL269933A (cg-RX-API-DMAC7.html) 2019-11-28
CR20230539A (es) 2024-04-08
US10961237B2 (en) 2021-03-30
SI3609886T1 (sl) 2024-05-31
HRP20240361T1 (hr) 2024-06-07
IL294175A (en) 2022-08-01
JP7581294B2 (ja) 2024-11-12
IL269933B (en) 2022-07-01
SG11201909224QA (en) 2019-11-28
NZ757929A (en) 2025-10-31
MA50013A (fr) 2020-07-08
CR20190517A (es) 2020-02-13
IL294175B1 (en) 2024-12-01
LT3609886T (lt) 2024-04-10
JP7145874B2 (ja) 2022-10-03
US10189829B2 (en) 2019-01-29
JOP20190233B1 (ar) 2024-04-18
EP4249071A2 (en) 2023-09-27
US11858926B2 (en) 2024-01-02
AU2022218560A1 (en) 2022-09-15
RS65386B1 (sr) 2024-04-30
ES2975769T3 (es) 2024-07-15
CO2019012571A2 (es) 2020-01-17
EP4249071A3 (en) 2024-01-24
KR20230164247A (ko) 2023-12-01
AU2024204241A1 (en) 2024-07-11
SA519410292B1 (ar) 2023-03-12
EP3609886A1 (en) 2020-02-19
FI3609886T3 (fi) 2024-03-26
US20200239459A1 (en) 2020-07-30
CN110621670B (zh) 2023-09-15
WO2018191577A1 (en) 2018-10-18
AR129632A2 (es) 2024-09-11
AU2022218560B2 (en) 2024-04-04
MA50013B1 (fr) 2024-05-31
US20230147490A1 (en) 2023-05-11
US20180297992A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
JP7778206B2 (ja) ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体
HK40100583A (en) Benzoazepine analogs as inhibiting agents for bruton’s tyrosine kinase
EA040817B1 (ru) Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона
EA047837B1 (ru) Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона
HK40022870B (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
HK40022870A (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
BR112019021399B1 (pt) Análogos de benzoazepina como agentes inibidores para tirosina quinase de bruton e seu uso, forma cristalina a e g e composição farmacêutica